Significant Responses to Platinum-based Chemotherapy in Renal Medullary Carcinoma

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2004 Dec 17

PMID 15602719

Citations 22

Authors

John J Strouse

Melissa Spevak

A Kyle Mack

Robert J Arceci

Donald Small

David M Loeb

Affiliations

Soon will be listed here.

Abstract

Most patients with renal medullary carcinoma (RMC) have advanced disease at presentation and rarely respond to radiation or chemotherapy. We describe two adolescents with metastatic disease who had significant responses to cisplatin or carboplatin in combination with gemcitabine and paclitaxel.

Citing Articles

Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers.

Perotti D, OSullivan M, Walz A, Davick J, Al-Saadi R, Benedetti D Nat Rev Urol. 2025; .

PMID: 39881003 DOI: 10.1038/s41585-024-00993-6.

Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.

Drobner J, Portal D, Runcie K, Yang Y, Singer E J Kidney Cancer VHL. 2023; 10(3):37-60.

PMID: 37789902 PMC: 10542704. DOI: 10.15586/jkcvhl.v10i3.295.

Surgical and oncological management of renal medullary carcinoma in a young patient: a case report.

Courcier J, De La Taille A, Bertolo R, Amparore D, Erdem S, Kara O Front Oncol. 2023; 13:1073728.

PMID: 37205186 PMC: 10185901. DOI: 10.3389/fonc.2023.1073728.

Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.

Sarkar S, Throckmorton W, Bingham R, Msaouel P, Genovese G, Slopis J Curr Oncol. 2023; 30(3):3355-3365.

PMID: 36975468 PMC: 10047671. DOI: 10.3390/curroncol30030255.

Recent Advances in Renal Medullary Carcinoma.

Su Y, Hong A Int J Mol Sci. 2022; 23(13).

PMID: 35806102 PMC: 9266801. DOI: 10.3390/ijms23137097.